Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > Game over

<< Previous

Bullboard Posts

Next >>

Comment by boozehound3on Aug 25, 2020 2:41pm

191 Views

Post# 31451534

RE:RE:Game over

Are you that naive. I didn't say the company had the news. Who do you think dumped two million shares last time. It's a leak from the trial and they will have known t2 results for
months now. Your right a lot has changed in the omega market for the worse. No one wants to explain why epamova failed. I still am of the opinion that amarin couldn't repeat their results if one works they all should work to some defgree. End of story

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!